25 November 2014
GlobalAcorn to Present at OBN CEO & Investor Networking Forum
London, UK—GlobalAcorn, a cancer nanomedicine biopharmaceutical company announced that Dr Nigel Whittle, Head of Commercial Development, will be showcasing the company’s corporate strategy at the OBN CEO & Investor Networking Forum on 25 November 2014. This prestigious event, held at Riverbank House, London, is an opportunity for venture, corporate venture, institutional and angel communities to take a first look at emerging innovative R&D companies.
The event includes keynote presentations by lead investors in life sciences, presentations by a limited number of early-stage R&D companies, and networking opportunities with 80 senior delegates from the investment and innovative R&D community.
GlobalAcorn is a cancer nanomedicine biopharmaceutical company dedicated to discovering and developing advanced therapeutics and diagnostics intended to transform the standard of care in treating and managing cancer.
GlobalAcorn is developing innovative pharmaceutical products that are expected to make significant contributions towards the evolving markets in companion diagnostics, image-guided therapies, stratified and personalized medicine.